Difficult to build a case for this as it is purely speculation and rumor that has highlighted the stock of NASDAQ:CLVS . There has been some option activity which is encouraging and positive trial data which failed to rally the stock. The contrarian long option is going against strong negatives such as, high debt, decreasing pricing power, insider selling and decreasing institutional ownership. This is a wait ans see and have alerts set for a break up or down.
Analyst Average Price Target $29.91 Analyst Recommendation Overweight Company Profile Clovis Oncology, Inc. is a commercial stage biotechnology company, which engages in the acquisition, development, and commercialization of cancer treatments in the United States, Europe, and other markets. Its product development programs target specific subsets of cancer, and simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from its use.